NVCR

In the past six months, NovoCure's stock has been impacted by several events. In late April 2026, the stock gapped up significantly after its Q1 2026 earnings report, where revenue beat expectations but EPS missed. Management raised its full-year 2026 revenue guidance. The launch of Optune Pax for pancreatic cancer has shown promising demand, though its sustainability is noted as uncertain, and Optune Lua for lung cancer has reportedly disappointed. Earlier in March 2026, NovoCure announced positive topline results from its Phase 2 PANOVA-4 clinical trial for TTFields therapy in metastatic pancreatic cancer, which met its primary endpoint. The company also underwent a leadership restructuring, and insider selling activity has been noted.